For a breakdown of Mediterrania Capital Partners’ deals and exits, visit our Dealmaker’s Log.
Laprophan, a Moroccan pharmaceutical company backed by private equity firm Mediterrania Capital Partners, has launched an initial public offering (IPO) on the Bourse de Casablanca.
The subscription period runs from 9 to 17 November 2026, and the shares are expected to start trading in early December, according to TelQuel.
It combines a capital increase of about MAD 1.4 billion ($140 million) with the sale of MAD 822 million ($82.2 million) in existing shares, according to La Vie éco.
Founded in 1949 by Abderrahim Bennis, the company distributes its own branded products as well as finished products imported from large international laboratories. It also exports to more than 30 countries across Africa and the Middle East.
Mediterrania, which focuses on growth investments in African small and mid-cap companies, acquired a stake in Laprophan in May 2023 through its fund MC IV. DEG, Proparco and FMO also invested in the €75 million deal.
Want to know who is raising, investing, and exiting in Africa? Get Africa Private Equity News’ monthly Dealmaker’s Log – a database of reported investment deals, exits, and fundraising closes. Access the latest Dealmaker’s Log here